Pargyline
Pargyline is a monoamine oxidase inhibitor (MAOI) that is primarily used as an antihypertensive agent. It works by inhibiting the activity of the enzyme monoamine oxidase, which is responsible for the breakdown of monoamine neurotransmitters such as dopamine, serotonin, and norepinephrine. By inhibiting this enzyme, pargyline increases the levels of these neurotransmitters in the brain, which can help to alleviate symptoms of depression and anxiety.
Mechanism of Action[edit | edit source]
Pargyline selectively inhibits monoamine oxidase type B (MAO-B), which is primarily involved in the catabolism of dopamine. This inhibition leads to an increase in the levels of dopamine in the brain, which can be beneficial in the treatment of Parkinson's disease and other conditions characterized by low dopamine levels. Additionally, by inhibiting the breakdown of other monoamines, pargyline can also have antidepressant effects.
Medical Uses[edit | edit source]
Pargyline is used in the treatment of hypertension and has been studied for its potential benefits in treating depression and Parkinson's disease. However, its use has declined with the development of newer medications with fewer side effects.
Side Effects[edit | edit source]
Common side effects of pargyline include dizziness, headache, nausea, and insomnia. More serious side effects can include hypertensive crisis if taken with foods high in tyramine or certain other medications. Patients taking pargyline must adhere to dietary restrictions to avoid these potentially dangerous interactions.
Interactions[edit | edit source]
Pargyline can interact with a variety of medications, including other antidepressants, sympathomimetic drugs, and certain anesthetics. It is important for patients to inform their healthcare provider of all medications they are taking to avoid adverse interactions.
History[edit | edit source]
Pargyline was developed in the mid-20th century and was one of the first MAOIs to be used clinically. Its use has decreased over time due to the development of newer antihypertensive and antidepressant medications with improved safety profiles.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
